- Home
- JPM vs LLY Comparison
JPM vs LLY Comparison
Compare JPM & LLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JPM | LLY |
|---|---|---|
| Founded | 1799 | 1876 |
| Country | United States | United States |
| Employees | 320079 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 809.5B | 818.6B |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | JPM | LLY |
|---|---|---|
| Price | $297.66 | $1,001.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 19 |
| Target Price | $331.93 | ★ $1,218.84 |
| AVG Volume (30 Days) | ★ 6.6M | 2.7M |
| Earning Date | 04-14-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.94% | 0.81% |
| EPS Growth | N/A | ★ 95.99 |
| EPS | N/A | ★ 8.26 |
| Revenue | N/A | ★ $65,179,000,000.00 |
| Revenue This Year | $18.51 | $27.15 |
| Revenue Next Year | $4.11 | $16.04 |
| P/E Ratio | ★ $15.42 | $121.77 |
| Revenue Growth | N/A | ★ 44.70 |
| 52 Week Low | $256.00 | $623.78 |
| 52 Week High | $337.25 | $1,133.95 |
Technical Indicators
Market Signals| Indicator | JPM | LLY |
|---|---|---|
| Relative Strength Index (RSI) | 41.78 | 60.23 |
| Support Level | $293.95 | $978.77 |
| Resistance Level | $317.78 | $1,108.78 |
| Average True Range (ATR) | 5.69 | 27.78 |
| MACD | -1.88 | 8.99 |
| Stochastic Oscillator | 10.99 | 87.59 |
Price Performance
Historical ComparisonAbout JPM JP Morgan Chase & Co.
JPMorgan is a leading global financial services firm with operations in 66 countries and over 318,000 employees as of year-end 2025. Under the JPMorgan brands, the bank holding company boasts a $4.9 trillion balance sheet and $2.68 trillion in deposits, as of March 2026. The firm generates its revenue across three core operating segments: consumer and community banking, the commercial and investment bank, and asset and wealth management. It maintains the top global ranking in investment banking fees with an 8.4% market share, serves millions of consumers through its network of over 5,000 US branches, and manages over $7.1 trillion in client assets within its wealth and asset management franchise.
About LLY Eli Lilly and Company
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.